Biotech RadarJobs updated

COMPANY

Accent Therapeutics

HQ: Lexington, MA source · accenttx.com ↗

Clinical Phase 2

Location: Lexington, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Breast Cancer Recurrent Ovarian Cancer High-grade Serous Ovarian Carcinoma Triple Negative Breast Cancer sqNSCLC Squamous Non-small-cell Lung Cancer Colorectal Cancer Metastatic Colon Cancer Rectal Adenocarcinoma Endometrial Cancer ATX-295 ATX-559

2Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including source ↗
  2. Trial start Phase 1: First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06799065First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian CancerPhase 1/Phase 2RecruitingMar 21, 2025Apr 30, 2027 (estimated)
NCT06625515First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined CancersPhase 1TerminatedOct 11, 2024Jan 9, 2026 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback